SecBot SecBot
EFFECT ·Filed Aug 4, 2026

GYRE

GYRE THERAPEUTICS, INC.
NEUTRAL
Impact 3/10
Horizonweeks Processed2mo ago SEC9999999995-26-002523
IPO/offering going effective
Actionable Insight • Neutral

Monitor for any Form 4 filings or prospectus supplements indicating actual resales by registered stockholders. The lock-up expiration dates (180 days to 18 months from the S-3 effective date) will be key catalysts for potential overhang.

DirectionNeutral
Confidencehigh
Horizonweeks
Latest settled — T+20d
GYRE ▲ +5.20% at T+20d
NEUTRAL call +5.20% · α vs SPY +6.44% · entry $6.15 → $6.47
Next anchor: T+60d in 8h
Latest observation: T+57 +34.25% FF3 residual α
Entry = T+0 close
Aug 4, 2026
via day close
T+1d
+1.30%
call +1.30% · α +1.50%
$6.23
settled 3mo ago
T+5d
+7.97%
call +7.97% · α +8.07%
$6.64
settled 3mo ago
T+20d
+5.20%
call +5.20% · α +6.44%
$6.47
settled 8w ago
T+60d
Pending
in 8h

Price Chart

Loading chart...

Executive Summary

The SEC declared effective Gyre Therapeutics' S-3 shelf registration on August 3, 2026, covering 31,302,863 shares for resale by former Cullgen stockholders and GNI USA. The company is not raising capital, and lock-up agreements restrict selling for 180 days to 18 months on a portion of shares, limiting near-term overhang.

Key Facts

  • Effectiveness date: August 3, 2026 (SEC file number 333-296957).
  • Shelf registration covers 31,302,863 shares of common stock for resale by former Cullgen stockholders and GNI USA.
  • Gyre Therapeutics is not selling any shares or raising capital in this offering.
  • Lock-up agreements restrict selling for 180 days to 18 months on a portion of registered shares.
  • Largest holder (GNI Japan entities, 64.8% owner) is only registering 14.1M of its 86.3M shares.

Financial Impact

No immediate capital raise; potential future dilution from resales is limited by lock-up restrictions.

dilution

Risk Factors

  • Resales by large holders after lock-up expirations could create downward pressure on the stock.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Investment Themes

Documents Analyzed

This report is based on 3 SEC documents filed with EDGAR.

DocumentAccession Number
EFFECT Filing (Primary)9999999995-26-002523
Document: 9999999995-26-002523-index.html9999999995-26-002523
Document: 9999999995-26-002523.txt9999999995-26-002523
12 reports for GYRE
Performance horizon
0% Hit rate @ T+20 0 of 3 directional calls Went positive at some point 0 of 3 best @ T+5▼ −0.15%Aug 7, 2026
Filters
Rows
Reports for GYRE — sortable, filterable
TypeNow
Oct 22, 2026
5d ago
8-K
NEUTRAL ★ 2/10
$5.85awaiting T+20—$6.53 (+11.62%)
Sep 1, 2026
8w ago
8-K
NEUTRAL ★ 4/10
$6.47 $7.35▲ +13.52%▲ +12.34%$6.53 (+0.93%)
Aug 26, 2026
8w ago
8-K
NEUTRAL ★ 4/10
$6.65 $7.43▲ +11.73%▲ +10.53%$6.53 (−1.80%)
Aug 7, 2026
11w ago
8-K
BEARISH ★ 6/10
$6.67 $6.86▼ −2.85%▼ −3.25%$6.53 (+2.10%)
Aug 4, 2026
12w ago
EFFECT
NEUTRAL ★ 3/10
$6.15 $6.47▲ +5.20%▲ +6.44%$6.53 (+6.18%)
Jul 13, 2026
15w ago
S-3/A
NEUTRAL ★ 3/10
$6.34 $6.64▲ +4.73%▲ +2.24%$6.53 (+3.00%)
Jun 2, 2026
21w ago
8-K
NEUTRAL ★ 4/10
$5.56 $6.52▲ +17.27%▲ +18.83%$6.53 (+17.45%)
May 14, 2026
23w ago
8-K
NEUTRAL ★ 5/10
$6.55 $5.86▼ −10.53%▼ −12.65%$6.53 (−0.31%)
May 4, 2026
25w ago
8-K / DEFA14A
BULLISH ★ 7/10
$7.92 $5.81▼ −26.64%▼ −32.29%$6.53 (−17.55%)
May 4, 2026
25w ago
Press Release
BULLISH ★ 7/10
$7.92 $5.81▼ −26.64%▼ −32.29%$6.53 (−17.55%)
Showing 10 of 12

US Market Status

Market Closed — Opens in 9h 27m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Aug 4, 2026